Navigation Links
Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
Date:11/5/2008

oking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(R) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on the Company's ADHD franchise; patents, including but not limited to, legal challenges relating to the Company's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); the Company's ability to secure new products for commercialization and/or development; the Company's ability to successfully integrate its stake in Jerini AG, as well as realize the anticipated benefits of the acquisition; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007.

For further information please contact:

Investor Cléa Rosenfeld (Rest of the World) +44-1256-894-160

Relations

Eric Rojas (North America) +1-617-551-9715

Media Jessica Mann (Rest of the World) +44-1256-894-280

Matthew Cabrey (North America) +1-484-595-8248

Jessica Cotrone (North America) +1-617-613-4640


'/>"/>
SOURCE Shire Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... company that develops and commercializes proprietary technologies and products ... operational results for the fiscal first quarter ended December ... in Canadian dollars (CAD), unless otherwise stated. ... new business from our existing customers and add to ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Horizon Therapeutics, Inc., a,privately held biopharmaceutical company, announced ... officer, will present a corporate,overview at the JMP ... October 7 at 9 a.m. ET at the ... Horizon Therapeutics, Inc. is a late-stage biopharmaceutical ...
... N.J., Oct. 1 SyntheMed, Inc. (OTC,Bulletin Board: ... commercialization of anti-adhesion products and other surgical,implants, announced ... of a,private placement in which it received $4.0 ... the issuance to investors of ten million units,at ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a ... matrix, today announced that it will,host a Research ... p.m. EDT. A,webcast of the presentations will be ... -- Strategic Company Overview, Jonathan Lim, M.D., ...
Cached Biology Technology:SyntheMed Completes $4.0 Million Equity Placement 2Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ... period 2013 through 2020. Also, a seven-year historic analysis is provided ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... the chemical marks littering the DNA inside our cells like ... at a time. But new high-throughput DNA sequencing technology has ... map the precise position of these individual DNA modifications throughout ... effect on the activity of any of Arabidopsis roughly 26,000 ...
... have struggled with plutonium contamination spreading further in groundwater ... and animals. It was known nanometer sized clusters ... had been able to study its structure or find ... Scientists at the U.S. Department of Energys Argonne ...
... scientists have uncovered details about the mechanisms through which ... cells, the researchers have linked ribosomes, the protein-making factories ... aids in the expression of genetic information, to the ... which was led by UW faculty members Brian Kennedy ...
Cached Biology News:Charting the epigenome 2Charting the epigenome 3Scientists discover how nanocluster contaminants increase risk of spreading 2Researchers uncover details about how dietary restriction slows down aging 2Researchers uncover details about how dietary restriction slows down aging 3
... cytoplasmic granules, is a key step ... (e.g. basophils, neutrophils, eosinophils, and mast ... secretory granules contain many proinflammatory mediators ... proteases (Hallgren, 2001). Tryptase, a tetrameric ...
... Custom Processing Service enables scientists who do not ... analysis software to have their biological samples tested ... Its as easy as 1-2-3 Chose ... your samples from the S&S antibody menu. ...
... sensitive nucleic acid gel stain has bright fluorescence ... gels, making it ideal for detecting dsDNA in ... SYBR Green I nucleic gel acid stain ... real-time PCR assays and bandshift assays. One mL ...
... Todays advanced protein cross-linking techniques are defined ... Dr. Shan S. Wong. This valuable hardcover ... schemes and current application references. More than ... protein cross-linking and conjugate preparation from ...
Biology Products: